Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Regeneron Q1 Eylea miss 'not about share, says Piper Sandler » 08:42
05/19/23
05/19
08:42
05/19/23
08:42
REGN

Regeneron

$747.30 /

-3.025 (-0.40%)

, RHHBY

Roche

$39.59 /

-0.23 (-0.58%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond highlights a new Spherix ophthalmology survey in "the aftermath of another down quarter for Eylea," reporting that the survey work indicates that Eylea "remains the clear intravitreal category leader in nAMD" with 42% patient share and Vabysmo still holds mid-single digit share despite "all of Roche's fanfare." However, Vabysmo momentum is building and the 8mg aflibercept PDUFA "an't come soon enough," added the analyst, who "increasingly" believes Regeneron (REGN) has "very little margin for error with regard to the high dose launch." Piper maintains an Overweight rating and $850 price target on Regeneron shares.

ShowHide Related Items >><<
RHHBY Roche
$39.59 /

-0.23 (-0.58%)

REGN Regeneron
$747.30 /

-3.025 (-0.40%)

REGN Regeneron
$747.30 /

-3.025 (-0.40%)

05/08/23 Guggenheim
Regeneron price target lowered to $935 from $960 at Guggenheim
05/05/23 Morgan Stanley
Regeneron price target raised to $927 from $880 at Morgan Stanley
05/05/23 SVB Securities
Regeneron price target lowered to $895 from $976 at SVB Securities
05/03/23 Truist
Regeneron price target raised to $1,050 from $856 at Truist
RHHBY Roche
$39.59 /

-0.23 (-0.58%)

04/10/23 BofA
BofA questions relevance of Briumvi tracking to Q1 beat, says TG move 'overdone'
03/27/23 Barclays
Roche downgraded to Equal Weight from Overweight at Barclays
03/16/23 Needham
Recursion Pharmaceuticals initiated with a Buy at Needham
RHHBY Roche
$39.59 /

-0.23 (-0.58%)

REGN Regeneron
$747.30 /

-3.025 (-0.40%)

RHHBY Roche
$39.59 /

-0.23 (-0.58%)

REGN Regeneron
$747.30 /

-3.025 (-0.40%)

RHHBY Roche
$39.59 /

-0.23 (-0.58%)

REGN Regeneron
$747.30 /

-3.025 (-0.40%)

REGN Regeneron
$747.30 /

-3.025 (-0.40%)

Hot Stocks
Genentech announces fenebrutinib study met primary, secondary endpoint » 05:23
05/17/23
05/17
05:23
05/17/23
05:23
RHHBY

Roche

$39.31 /

-0.48 (-1.21%)

Genentech, a member of…

Genentech, a member of Roche, announced results from the Phase II FENopta study evaluating investigational oral fenebrutinib in adults with relapsing forms of multiple sclerosis, or RMS. The study met its primary and secondary endpoints, showing oral fenebrutinib significantly reduced magnetic resonance imaging, or MRI, markers of MS disease activity in the brain compared to placebo. Additionally, pre-clinical data have shown fenebrutinib to be potent and highly selective, and it is the only reversible inhibitor currently in Phase III trials for MS. Fenebrutinib significantly reduced the total number of new gadolinium-enhancing T1 brain lesions compared to placebo, the primary endpoint of the trial. Additionally, fenebrutinib significantly reduced the total number of new or enlarging T2 brain lesions compared to placebo, a secondary endpoint. Furthermore, a higher proportion of patients treated with fenebrutinib were free from any new gadolinium-enhancing T1 brain lesions and new or enlarging T2-weighted brain lesions compared to placebo. T1 lesions, as measured by MRI, are a marker of active inflammation and T2 lesions represent the amount of disease burden or lesion load. The safety profile of fenebrutinib was consistent with previous and ongoing fenebrutinib clinical trials across more than 2,400 people to date. There were no new safety concerns identified in the FENopta study.

ShowHide Related Items >><<
RHHBY Roche
$39.31 /

-0.48 (-1.21%)

RHHBY Roche
$39.31 /

-0.48 (-1.21%)

05/08/23 Guggenheim
Regeneron price target lowered to $935 from $960 at Guggenheim
04/10/23 BofA
BofA questions relevance of Briumvi tracking to Q1 beat, says TG move 'overdone'
03/27/23 Barclays
Roche downgraded to Equal Weight from Overweight at Barclays
03/16/23 Needham
Recursion Pharmaceuticals initiated with a Buy at Needham
RHHBY Roche
$39.31 /

-0.48 (-1.21%)

RHHBY Roche
$39.31 /

-0.48 (-1.21%)

RHHBY Roche
$39.31 /

-0.48 (-1.21%)

Conference/Events
Capital One biotech analysts to hold an analyst/industry conference call » 07:50
05/12/23
05/12
07:50
05/12/23
07:50
RHHBY

Roche

$39.56 /

+0.01 (+0.03%)

, LLY

Eli Lilly

$434.52 /

-0.26 (-0.06%)

, AZN

AstraZeneca

$74.74 /

-0.145 (-0.19%)

, ARVN

Arvinas

$22.88 /

-1.335 (-5.51%)

, OLMA

Olema Oncology

$6.81 /

+0.16 (+2.41%)

Biotech Analyst Jallah,…

Biotech Analyst Jallah, along with a Key Opinion Leader, discuss drugs in development for HR+ HER2- Breast Cancer including ones from Roche, Lilly, AstraZeneca, Arvinas and Olema on an Analyst/Industry conference call to be held on May 12 at 1 pm. Webcast Link

ShowHide Related Items >><<
RHHBY Roche
$39.56 /

+0.01 (+0.03%)

OLMA Olema Oncology
$6.81 /

+0.16 (+2.41%)

LLY Eli Lilly
$434.52 /

-0.26 (-0.06%)

AZN AstraZeneca
$74.74 /

-0.145 (-0.19%)

ARVN Arvinas
$22.88 /

-1.335 (-5.51%)

RHHBY Roche
$39.56 /

+0.01 (+0.03%)

05/08/23 Guggenheim
Regeneron price target lowered to $935 from $960 at Guggenheim
04/10/23 BofA
BofA questions relevance of Briumvi tracking to Q1 beat, says TG move 'overdone'
03/27/23 Barclays
Roche downgraded to Equal Weight from Overweight at Barclays
03/16/23 Needham
Recursion Pharmaceuticals initiated with a Buy at Needham
LLY Eli Lilly
$434.52 /

-0.26 (-0.06%)

05/04/23 BMO Capital
Eli Lilly price target raised to $505 from $430 at BMO Capital
05/04/23 BofA
Biogen price target raised to $320 from $300 at BofA
05/04/23 JPMorgan
Eli Lilly price target raised to $475 from $430 at JPMorgan
AZN AstraZeneca
$74.74 /

-0.145 (-0.19%)

05/09/23 Berenberg
AstraZeneca price target raised to 135 GBp from 124 GBp at Berenberg
04/28/23 JPMorgan
AstraZeneca price target raised to 14,000 GBp from 13,500 GBp at JPMorgan
04/13/23 Argus
AstraZeneca price target raised to $85 from $75 at Argus
04/11/23 Guggenheim
AstraZeneca price target lowered to 11,900 GBp from 12,700 GBp at Guggenheim
ARVN Arvinas
$22.88 /

-1.335 (-5.51%)

05/08/23 Stifel
Arvinas price target lowered to $72 from $75 at Stifel
03/18/23 Citi
Arvinas price target raised to $77 from $72 at Citi
02/23/23 Capital One
Arvinas remains one of the best biotechs to own, says Capital One
01/17/23 Truist
Arvinas price target lowered to $65 from $100 at Truist
OLMA Olema Oncology
$6.81 /

+0.16 (+2.41%)

05/11/23 H.C. Wainwright
Olema Oncology price target raised to $17 from $14 at H.C. Wainwright
05/10/23 Capital One
Olema Oncology updates in line with expectations, says Capital One
05/10/23 H.C. Wainwright
Olema Oncology price target lowered to $14 from $15 at H.C. Wainwright
05/05/23 Capital One
Capital One starts Olema at Buy, sees 200% potential upside
RHHBY Roche
$39.56 /

+0.01 (+0.03%)

OLMA Olema Oncology
$6.81 /

+0.16 (+2.41%)

LLY Eli Lilly
$434.52 /

-0.26 (-0.06%)

AZN AstraZeneca
$74.74 /

-0.145 (-0.19%)

ARVN Arvinas
$22.88 /

-1.335 (-5.51%)

RHHBY Roche
$39.56 /

+0.01 (+0.03%)

LLY Eli Lilly
$434.52 /

-0.26 (-0.06%)

AZN AstraZeneca
$74.74 /

-0.145 (-0.19%)

RHHBY Roche
$39.56 /

+0.01 (+0.03%)

OLMA Olema Oncology
$6.81 /

+0.16 (+2.41%)

LLY Eli Lilly
$434.52 /

-0.26 (-0.06%)

AZN AstraZeneca
$74.74 /

-0.145 (-0.19%)

LLY Eli Lilly
$434.52 /

-0.26 (-0.06%)

AZN AstraZeneca
$74.74 /

-0.145 (-0.19%)

Conference/Events
Capital One biotech analysts to hold an analyst/industry conference call » 04:55
05/12/23
05/12
04:55
05/12/23
04:55
RHHBY

Roche

$39.56 /

+0.01 (+0.03%)

, LLY

Eli Lilly

$434.52 /

-0.26 (-0.06%)

, AZN

AstraZeneca

$74.74 /

-0.145 (-0.19%)

, ARVN

Arvinas

$22.88 /

-1.335 (-5.51%)

, OLMA

Olema Oncology

$6.81 /

+0.16 (+2.41%)

Biotech Analyst Jallah,…

Biotech Analyst Jallah, along with a Key Opinion Leader, discuss drugs in development for HR+ HER2- Breast Cancer including ones from Roche, Lilly, AstraZeneca, Arvinas and Olema on an Analyst/Industry conference call to be held on May 12 at 1 pm. Webcast Link

ShowHide Related Items >><<
RHHBY Roche
$39.56 /

+0.01 (+0.03%)

OLMA Olema Oncology
$6.81 /

+0.16 (+2.41%)

LLY Eli Lilly
$434.52 /

-0.26 (-0.06%)

AZN AstraZeneca
$74.74 /

-0.145 (-0.19%)

ARVN Arvinas
$22.88 /

-1.335 (-5.51%)

RHHBY Roche
$39.56 /

+0.01 (+0.03%)

05/08/23 Guggenheim
Regeneron price target lowered to $935 from $960 at Guggenheim
04/10/23 BofA
BofA questions relevance of Briumvi tracking to Q1 beat, says TG move 'overdone'
03/27/23 Barclays
Roche downgraded to Equal Weight from Overweight at Barclays
03/16/23 Needham
Recursion Pharmaceuticals initiated with a Buy at Needham
LLY Eli Lilly
$434.52 /

-0.26 (-0.06%)

05/04/23 BMO Capital
Eli Lilly price target raised to $505 from $430 at BMO Capital
05/04/23 BofA
Biogen price target raised to $320 from $300 at BofA
05/04/23 JPMorgan
Eli Lilly price target raised to $475 from $430 at JPMorgan
AZN AstraZeneca
$74.74 /

-0.145 (-0.19%)

05/09/23 Berenberg
AstraZeneca price target raised to 135 GBp from 124 GBp at Berenberg
04/28/23 JPMorgan
AstraZeneca price target raised to 14,000 GBp from 13,500 GBp at JPMorgan
04/13/23 Argus
AstraZeneca price target raised to $85 from $75 at Argus
04/11/23 Guggenheim
AstraZeneca price target lowered to 11,900 GBp from 12,700 GBp at Guggenheim
ARVN Arvinas
$22.88 /

-1.335 (-5.51%)

05/08/23 Stifel
Arvinas price target lowered to $72 from $75 at Stifel
03/18/23 Citi
Arvinas price target raised to $77 from $72 at Citi
02/23/23 Capital One
Arvinas remains one of the best biotechs to own, says Capital One
01/17/23 Truist
Arvinas price target lowered to $65 from $100 at Truist
OLMA Olema Oncology
$6.81 /

+0.16 (+2.41%)

05/11/23 H.C. Wainwright
Olema Oncology price target raised to $17 from $14 at H.C. Wainwright
05/10/23 Capital One
Olema Oncology updates in line with expectations, says Capital One
05/10/23 H.C. Wainwright
Olema Oncology price target lowered to $14 from $15 at H.C. Wainwright
05/05/23 Capital One
Capital One starts Olema at Buy, sees 200% potential upside
RHHBY Roche
$39.56 /

+0.01 (+0.03%)

OLMA Olema Oncology
$6.81 /

+0.16 (+2.41%)

LLY Eli Lilly
$434.52 /

-0.26 (-0.06%)

AZN AstraZeneca
$74.74 /

-0.145 (-0.19%)

ARVN Arvinas
$22.88 /

-1.335 (-5.51%)

RHHBY Roche
$39.56 /

+0.01 (+0.03%)

LLY Eli Lilly
$434.52 /

-0.26 (-0.06%)

AZN AstraZeneca
$74.74 /

-0.145 (-0.19%)

RHHBY Roche
$39.56 /

+0.01 (+0.03%)

OLMA Olema Oncology
$6.81 /

+0.16 (+2.41%)

LLY Eli Lilly
$434.52 /

-0.26 (-0.06%)

AZN AstraZeneca
$74.74 /

-0.145 (-0.19%)

LLY Eli Lilly
$434.52 /

-0.26 (-0.06%)

AZN AstraZeneca
$74.74 /

-0.145 (-0.19%)

Conference/Events
Capital One biotech analysts to hold an analyst/industry conference call » 22:59
05/11/23
05/11
22:59
05/11/23
22:59
RHHBY

Roche

$39.56 /

+0.01 (+0.03%)

, LLY

Eli Lilly

$435.65 /

-0.26 (-0.06%)

, AZN

AstraZeneca

$74.74 /

-0.145 (-0.19%)

, ARVN

Arvinas

$22.88 /

-1.335 (-5.51%)

, OLMA

Olema Oncology

$6.81 /

+0.16 (+2.41%)

Biotech Analyst Jallah,…

Biotech Analyst Jallah, along with a Key Opinion Leader, discuss drugs in development for HR+ HER2- Breast Cancer including ones from Roche, Lilly, AstraZeneca, Arvinas and Olema on an Analyst/Industry conference call to be held on May 12 at 8 am. Webcast Link

ShowHide Related Items >><<
RHHBY Roche
$39.56 /

+0.01 (+0.03%)

OLMA Olema Oncology
$6.81 /

+0.16 (+2.41%)

LLY Eli Lilly
$435.65 /

-0.26 (-0.06%)

AZN AstraZeneca
$74.74 /

-0.145 (-0.19%)

ARVN Arvinas
$22.88 /

-1.335 (-5.51%)

RHHBY Roche
$39.56 /

+0.01 (+0.03%)

05/08/23 Guggenheim
Regeneron price target lowered to $935 from $960 at Guggenheim
04/10/23 BofA
BofA questions relevance of Briumvi tracking to Q1 beat, says TG move 'overdone'
03/27/23 Barclays
Roche downgraded to Equal Weight from Overweight at Barclays
03/16/23 Needham
Recursion Pharmaceuticals initiated with a Buy at Needham
LLY Eli Lilly
$435.65 /

-0.26 (-0.06%)

05/04/23 BMO Capital
Eli Lilly price target raised to $505 from $430 at BMO Capital
05/04/23 BofA
Biogen price target raised to $320 from $300 at BofA
05/04/23 JPMorgan
Eli Lilly price target raised to $475 from $430 at JPMorgan
AZN AstraZeneca
$74.74 /

-0.145 (-0.19%)

05/09/23 Berenberg
AstraZeneca price target raised to 135 GBp from 124 GBp at Berenberg
04/28/23 JPMorgan
AstraZeneca price target raised to 14,000 GBp from 13,500 GBp at JPMorgan
04/13/23 Argus
AstraZeneca price target raised to $85 from $75 at Argus
04/11/23 Guggenheim
AstraZeneca price target lowered to 11,900 GBp from 12,700 GBp at Guggenheim
ARVN Arvinas
$22.88 /

-1.335 (-5.51%)

05/08/23 Stifel
Arvinas price target lowered to $72 from $75 at Stifel
03/18/23 Citi
Arvinas price target raised to $77 from $72 at Citi
02/23/23 Capital One
Arvinas remains one of the best biotechs to own, says Capital One
01/17/23 Truist
Arvinas price target lowered to $65 from $100 at Truist
OLMA Olema Oncology
$6.81 /

+0.16 (+2.41%)

05/11/23 H.C. Wainwright
Olema Oncology price target raised to $17 from $14 at H.C. Wainwright
05/10/23 Capital One
Olema Oncology updates in line with expectations, says Capital One
05/10/23 H.C. Wainwright
Olema Oncology price target lowered to $14 from $15 at H.C. Wainwright
05/05/23 Capital One
Capital One starts Olema at Buy, sees 200% potential upside
RHHBY Roche
$39.56 /

+0.01 (+0.03%)

OLMA Olema Oncology
$6.81 /

+0.16 (+2.41%)

LLY Eli Lilly
$435.65 /

-0.26 (-0.06%)

AZN AstraZeneca
$74.74 /

-0.145 (-0.19%)

ARVN Arvinas
$22.88 /

-1.335 (-5.51%)

RHHBY Roche
$39.56 /

+0.01 (+0.03%)

LLY Eli Lilly
$435.65 /

-0.26 (-0.06%)

AZN AstraZeneca
$74.74 /

-0.145 (-0.19%)

RHHBY Roche
$39.56 /

+0.01 (+0.03%)

OLMA Olema Oncology
$6.81 /

+0.16 (+2.41%)

LLY Eli Lilly
$435.65 /

-0.26 (-0.06%)

AZN AstraZeneca
$74.74 /

-0.145 (-0.19%)

LLY Eli Lilly
$435.65 /

-0.26 (-0.06%)

AZN AstraZeneca
$74.74 /

-0.145 (-0.19%)

Periodicals
BioNTech data was reported in June 2022, Reuters reports » 12:33
05/10/23
05/10
12:33
05/10/23
12:33
BNTX

BioNTech

$104.50 /

-0.215 (-0.21%)

, RHHBY

Roche

$39.80 /

-0.16 (-0.40%)

A personalized treatment…

A personalized treatment based on messenger RNA by BioNTech (BNTX) may bode well for the future of fighting pancreatic cancer, with results of a trial showing that half of the 16 trial participants, who had undergone surgery to remove their tumor, had developed T cells that can potentially recognize cancerous cells and stop them from re-emerging, Reuters' Ludwig Burger reports, citing scientific journal Nature. The publication notes that BioNTech, which co-developed the treatment with Roche's (RHHBY) Genentech, first reported the data in June 2022. Reference Link

ShowHide Related Items >><<
RHHBY Roche
$39.80 /

-0.16 (-0.40%)

BNTX BioNTech
$104.50 /

-0.215 (-0.21%)

BNTX BioNTech
$104.50 /

-0.215 (-0.21%)

03/30/23 Morgan Stanley
BioNTech could be up 20%-30% if PCV readout impresses, says Morgan Stanley
03/28/23 Morgan Stanley
BioNTech price target lowered to $150 from $216 at Morgan Stanley
03/28/23 Canaccord
BioNTech price target raised to $203 from $191 at Canaccord
03/28/23 TD Cowen
BioNTech price target lowered to $130 from $145 at TD Cowen
RHHBY Roche
$39.80 /

-0.16 (-0.40%)

05/08/23 Guggenheim
Regeneron price target lowered to $935 from $960 at Guggenheim
04/10/23 BofA
BofA questions relevance of Briumvi tracking to Q1 beat, says TG move 'overdone'
03/27/23 Barclays
Roche downgraded to Equal Weight from Overweight at Barclays
03/16/23 Needham
Recursion Pharmaceuticals initiated with a Buy at Needham
RHHBY Roche
$39.80 /

-0.16 (-0.40%)

BNTX BioNTech
$104.50 /

-0.215 (-0.21%)

RHHBY Roche
$39.80 /

-0.16 (-0.40%)

BNTX BioNTech
$104.50 /

-0.215 (-0.21%)

RHHBY Roche
$39.80 /

-0.16 (-0.40%)

BNTX BioNTech
$104.50 /

-0.215 (-0.21%)

Hot Stocks
Genentech announces FDA acceptance of Vabysmo sBLA » 05:44
05/09/23
05/09
05:44
05/09/23
05:44
RHHBY

Roche

$39.96 /

+0.17 (+0.43%)

Genentech, a member of…

Genentech, a member of Roche, announced that the FDA has accepted the company's supplemental Biologics License Application, or sBLA, for Vabysmo for the treatment of macular edema following retinal vein occlusion, or RVO. The sBLA is based on results from the Phase III BALATON and COMINO studies that demonstrated treatment with Vabysmo provided early and sustained improvement in vision, meeting the primary endpoint of non-inferior visual acuity gains at 24 weeks compared to aflibercept. Vabysmo's safety profile was consistent with previous trials.

ShowHide Related Items >><<
RHHBY Roche
$39.96 /

+0.17 (+0.43%)

RHHBY Roche
$39.96 /

+0.17 (+0.43%)

05/08/23 Guggenheim
Regeneron price target lowered to $935 from $960 at Guggenheim
04/10/23 BofA
BofA questions relevance of Briumvi tracking to Q1 beat, says TG move 'overdone'
03/27/23 Barclays
Roche downgraded to Equal Weight from Overweight at Barclays
03/16/23 Needham
Recursion Pharmaceuticals initiated with a Buy at Needham
RHHBY Roche
$39.96 /

+0.17 (+0.43%)

RHHBY Roche
$39.96 /

+0.17 (+0.43%)

RHHBY Roche
$39.96 /

+0.17 (+0.43%)

Recommendations
Regeneron price target lowered to $935 from $960 at Guggenheim » 10:21
05/08/23
05/08
10:21
05/08/23
10:21
REGN

Regeneron

$752.42 /

-8.89 (-1.17%)

, RHHBY

Roche

$39.79 /

+0.15 (+0.38%)

Guggenheim analyst Yatin…

Guggenheim analyst Yatin Suneja lowered the firm's price target on Regeneron (REGN) to $935 from $960 and keeps a Buy rating on the shares following quarterly results. While the temporary copay issues from Q4 have been resolved, Eylea U.S. sales were down on competitive pressures and inventory dynamics, the firm notes. Pressure from Roche's (RHHBY) Vabysmo is growing and likely to persist until HD Eylea is launched, Guggenheim adds.

ShowHide Related Items >><<
RHHBY Roche
$39.79 /

+0.15 (+0.38%)

REGN Regeneron
$752.42 /

-8.89 (-1.17%)

REGN Regeneron
$752.42 /

-8.89 (-1.17%)

05/05/23 Morgan Stanley
Regeneron price target raised to $927 from $880 at Morgan Stanley
05/05/23 SVB Securities
Regeneron price target lowered to $895 from $976 at SVB Securities
05/03/23 Truist
Regeneron price target raised to $1,050 from $856 at Truist
04/20/23 TD Cowen
Regeneron price target raised to $885 from $875 at TD Cowen
RHHBY Roche
$39.79 /

+0.15 (+0.38%)

04/10/23 BofA
BofA questions relevance of Briumvi tracking to Q1 beat, says TG move 'overdone'
03/27/23 Barclays
Roche downgraded to Equal Weight from Overweight at Barclays
03/16/23 Needham
Recursion Pharmaceuticals initiated with a Buy at Needham
02/27/23 Societe Generale
Societe Generale upgrades Roche to Buy, says 'enough is enough'
RHHBY Roche
$39.79 /

+0.15 (+0.38%)

REGN Regeneron
$752.42 /

-8.89 (-1.17%)

RHHBY Roche
$39.79 /

+0.15 (+0.38%)

RHHBY Roche
$39.79 /

+0.15 (+0.38%)

REGN Regeneron
$752.42 /

-8.89 (-1.17%)

REGN Regeneron
$752.42 /

-8.89 (-1.17%)

Over a month ago
Hot Stocks
Roche reports CHMP recommends EU approval of fixed-duration Columvi » 12:52
04/26/23
04/26
12:52
04/26/23
12:52
RHHBY

Roche

$39.85 /

+0.2 (+0.50%)

Roche announced that the…

Roche announced that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has recommended the approval of Columvi for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, or DLBCL, after two or more lines of systemic therapy. A final decision is expected from the European Commission in the "near future," the company said. "New therapeutic options that are readily and broadly available are urgently needed for people with relapsing diffuse large B-cell lymphoma, which can become fatal without immediate treatment. The CHMP's recommendation for Columvi brings us closer to providing a new, fixed-duration therapy for people with diffuse large B-cell lymphoma that induces early and long-lasting responses," said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development.

ShowHide Related Items >><<
RHHBY Roche
$39.85 /

+0.2 (+0.50%)

RHHBY Roche
$39.85 /

+0.2 (+0.50%)

04/10/23 BofA
BofA questions relevance of Briumvi tracking to Q1 beat, says TG move 'overdone'
03/27/23 Barclays
Roche downgraded to Equal Weight from Overweight at Barclays
03/16/23 Needham
Recursion Pharmaceuticals initiated with a Buy at Needham
02/27/23 Societe Generale
Societe Generale upgrades Roche to Buy, says 'enough is enough'
RHHBY Roche
$39.85 /

+0.2 (+0.50%)

RHHBY Roche
$39.85 /

+0.2 (+0.50%)

RHHBY Roche
$39.85 /

+0.2 (+0.50%)

Hot Stocks
Zentalis enters agreements with Foundation Medicine, Roche » 10:07
04/26/23
04/26
10:07
04/26/23
10:07
ZNTL

Zentalis

$21.57 /

-0.21 (-0.96%)

, RHHBY

Roche

$39.85 /

+0.2 (+0.50%)

The Company announced…

The Company announced separate agreements with Foundation Medicine, Inc., an independent affiliate of the Roche Group, and with Roche Diagnostics. The current Foundation Medicine partnership involves global prospective genomic profiling for potential patient enrollment in Zentalis' Phase 2 clinical trial of azenosertib in Cyclin E1 driven high-grade serous ovarian cancer. The companies are also exploring opportunities to develop Foundation Medicine's tissue-based next generation sequencing assay as a companion diagnostic for azenosertib. The Roche Diagnostics agreement is focused on the development of an immunohistochemistry-based clinical trial assay that evaluates Cyclin E1 protein levels and that can potentially identify a broader patient population with high protein expression in the absence of amplification.

ShowHide Related Items >><<
ZNTL Zentalis
$21.57 /

-0.21 (-0.96%)

RHHBY Roche
$39.85 /

+0.2 (+0.50%)

ZNTL Zentalis
$21.57 /

-0.21 (-0.96%)

03/15/23 Stifel
Zentalis price target lowered to $46 from $55 at Stifel
11/14/22 Wedbush
Zentalis price target lowered to $32 from $51 at Wedbush
11/14/22 Wells Fargo
Zentalis price target lowered to $46 from $52 at Wells Fargo
11/10/22 Oppenheimer
Zentalis price target lowered to $50 from $80 at Oppenheimer
RHHBY Roche
$39.85 /

+0.2 (+0.50%)

04/10/23 BofA
BofA questions relevance of Briumvi tracking to Q1 beat, says TG move 'overdone'
03/27/23 Barclays
Roche downgraded to Equal Weight from Overweight at Barclays
03/16/23 Needham
Recursion Pharmaceuticals initiated with a Buy at Needham
02/27/23 Societe Generale
Societe Generale upgrades Roche to Buy, says 'enough is enough'
ZNTL Zentalis
$21.57 /

-0.21 (-0.96%)

RHHBY Roche
$39.85 /

+0.2 (+0.50%)

  • 16
    May
RHHBY Roche
$39.85 /

+0.2 (+0.50%)

ZNTL Zentalis
$21.57 /

-0.21 (-0.96%)

RHHBY Roche
$39.85 /

+0.2 (+0.50%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.